Endocrine Cancer
Feature
White House unveils plan to combat endocrine-disrupting PFAS pollution
The Biden administration announces actions by federal agencies to protect Americans from per- and polyfluoroalkyl substances.
Conference Coverage
Although inconclusive, CV safety study of cancer therapy attracts attention
Even though PRONOUNCE, a trial comparing prostate cancer drugs for cardiovascular safety couldn’t reach a conclusion, it may prove to be a model...
From the Journals
Possible obesity effect detected in cancer death rates
As with heart disease, declines in mortality for some cancers seem to be affected by the obesity epidemic.
From the Journals
AHA statement flags CV risk of hormonal cancer therapies
The American Heart Association outlines cardiovascular risks associated with hormonal therapies for breast and prostate cancer and provides...
Conference Coverage
ATA risk stratification for DTC performs well in real-world cohort
NEW ORLEANS – The risk stratification system also worked well as a predictor of disease-specific survival.
From the Journals
PCOS linked to increased cancer risk in premenopausal women
The increased risks appear to subside after menopause.
From the Journals
CTCs linked to late recurrence in HER2–, HR+ breast cancer
Study is the first to show that this CTC assay may play a role in determining late clinical recurrence after local and systemic adjuvant therapy...
Conference Coverage
U.S. pancreatic insufficiency patients often get inadequate enzyme replacement
U.S. insurance claims data during 2006-2013 show that patients with presumed exocrine pancreatic insufficiency often go undertreated.
Conference Coverage
Pancreatic cancer has a pancreatopathy distinct from type 2 diabetes
WASHINGTON – The relationship between pancreatic cancer and diabetes is complex, but certain pathological markers differentiate them.
Conference Coverage
Diabetes from checkpoint inhibitors probably means lifelong insulin
CHICAGO – In the largest case series to date, almost all patients remained on insulin at a median follow-up of 44 weeks, even after stopping ICIs...
Conference Coverage
New and improved classifiers may sharpen thyroid nodule diagnosis
VICTORIA, B.C. – The tests could improve preoperative assessment, even in histologic subsets that pose diagnostic challenges.